Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer
Wuqing Huang et al.
NATURE COMMUNICATIONS (2020)
Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma
Su Jong Yu et al.
JOURNAL OF HEPATOLOGY (2019)
Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer
Khaled Greish et al.
JOURNAL OF DRUG TARGETING (2018)
The Rationale for Repurposing Sildenafil for Lung Cancer Treatment
Theodore Keats et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2018)
PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery
K-E Andersson
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity
Lee-Hwa Tai et al.
ONCOIMMUNOLOGY (2018)
Recurrence-free Survival after radical Prostatectomy and PDE-5 Inhibitor Intake
L. Hofer et al.
UROLOGE (2017)
Recurrence-free Survival after radical Prostatectomy and PDE-5 Inhibitor Intake
L. Hofer et al.
UROLOGE (2017)
Phosphodiesterase type 5 and cancers: progress and challenges
Ines Barone et al.
ONCOTARGET (2017)
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment
Stacy Loeb et al.
EUROPEAN UROLOGY (2016)
Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer.
Michael S. Leapman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Joseph A. Califano et al.
CLINICAL CANCER RESEARCH (2015)
A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy
Andrea Gallina et al.
EUROPEAN UROLOGY (2015)
Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy
Uwe Michl et al.
JOURNAL OF UROLOGY (2015)
Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Donald T. Weed et al.
CLINICAL CANCER RESEARCH (2015)
Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma
Kimberly A. Noonan et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Erectile function outcome reporting after clinically localized prostate cancer treatment
Arthur L. Burnett et al.
JOURNAL OF UROLOGY (2007)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Paolo Serafini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells
M Sarfati et al.
BLOOD (2003)
Share Paper
